BUZZ-<a href="https://laohu8.com/S/NUVB">Nuvation Bio</a> rises on brain cancer drug data** Shares of drugmaker Nuvation Bio NUVB.N rise 1.5% to $7.58 premarket
** Co says experimental drug safusidenib met main goal in mid-stage trial for grade 2 IDH1-mutant glioma, a type of brain cancer
** 44% of patients saw tumors shrink or disappear; 88% had no disease progression after two years, co says
** Co plans to expand study into larger trial after FDA agreement on design changes - NUVB
** NUVB's safusidenib is an oral drug targeting tumors with IDH1 mutation, co says
** Up to last close, stock was up ~181% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments